Can beta-glucuronidase-producing gut bacteria prolong mucosal exposure to xenobiotics?

The liver utilizes UDP-glucuronosyltransferases (UGTs) to conjugate xenobiotics with polar glucuronic acid, converting lipophilic substances into water-soluble conjugates for biliary excretion. Once in the intestine, specific gut microbiota express beta-glucuronidase (GUS) enzymes that reverse this protective host pathway.

Molecular mechanism of reactivation

• Enzymatic cleavage: Bacterial GUS utilizes a double-displacement mechanism with conserved acidic residues to hydrolyze the glycosidic bond of glucuronide conjugates.
• Regeneration of active compounds: This cleavage releases the glucuronic acid moiety for microbial metabolism, returning the parent xenobiotic to its active, lipophilic aglycone state within the intestinal lumen.

Enterohepatic recirculation and mucosal toxicity

• Increased systemic exposure: The liberated lipophilic aglycones are readily reabsorbed across the intestinal mucosa and returned to the portal circulation, which directly drives enterohepatic recirculation and prolongs systemic drug half-life.
• Localized mucosal injury: Prolonged mucosal exposure to these reactivated irritants—such as active NSAIDs (e.g., diclofenac) or the chemotherapeutic metabolite SN-38 (from irinotecan)—induces direct epithelial injury, mucosal inflammation, ulceration, and clinical enteropathy or diarrhea.
• Therapeutic target: Research demonstrates that pharmacological inhibition of gut microbial GUS prevents local mucosal toxicity without altering systemic drug concentrations, confirming local deconjugation as the primary mediator of these side effects.

Bottom line

• Gut microbial beta-glucuronidases directly reverse host detoxification by deconjugating glucuronidated xenobiotics, which drives enterohepatic recirculation and prolongs mucosal exposure to cytotoxic agents, causing localized intestinal injury.